The short version
What teams need to understand
- Pharmacovigilance vendors must be monitored continuously using defined performance metrics.
- Key performance indicators must assess timeliness, quality, and compliance of vendor activities.
- Performance monitoring must include review of case processing timelines, data quality, and regulatory compliance.
- Results must be reviewed regularly and discussed through governance processes.
- Performance issues must trigger escalation and corrective action.
- Inspection-ready evidence must demonstrate active and ongoing monitoring of vendor performance.
Regulatory expectation
What regulators expect
Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.
- Vendor performance must be monitored using defined metrics.
- Performance monitoring must cover timeliness, quality, and compliance.
- Performance data must be reviewed regularly.
- Performance issues must be identified and addressed.
- The MAH must maintain visibility and control over vendor performance.
Why it matters
What this means in practice
Inspectors assess whether pharmacovigilance vendors are monitored through structured performance metrics and oversight processes. They typically review KPIs, audit results, trend analysis, and evidence that performance issues are identified and managed effectively.
Questions this page answers
Inspection evidence
Evidence teams should be able to show
Vendor KPI Reports
- ICSR reporting timeliness metrics
- Case quality scores and QC error rates
- Follow-up completion rates
- Compliance with agreed service levels
- Trend analysis of performance over time
Vendor Oversight Plan
- Defined monitoring activities and frequency
- Governance and communication schedule
- Roles responsible for vendor oversight
- Risk-based monitoring approach
Performance Review and Governance Records
- Regular vendor review meetings
- Discussion of KPI performance and trends
- Documentation of performance issues
- Action items arising from reviews
Audit and Quality Review Outputs
- Vendor audit reports
- Findings related to performance and compliance
- CAPA triggered by performance issues
- Follow-up verification of improvements
Issue Logs and Escalation Records
- Documented vendor performance issues
- Severity classification of issues
- Escalation to senior management
- Tracking of issue resolution
Regulatory Basis (Primary Sources)
- GVP Module I - requirement for oversight of outsourced pharmacovigilance activities
- GVP Module VI - need for compliant handling of safety data through controlled processes
- ICH E2D - expectations for maintaining compliant safety data management systems
- MHRA GPvP guidance - expectations for monitoring vendor performance
- FDA pharmacovigilance guidance - requirement to ensure compliance of outsourced activities
Typical Inspection Questions (What Inspectors Ask)
- How do you monitor your vendor's performance?
- What KPIs do you track for vendor activities?
- Show me performance reports for this vendor.
- How do you identify and manage performance issues?
- What actions were taken when performance dropped?
Common failure patterns
What good looks like
- Defined KPIs covering all critical vendor activities.
- Regular monitoring and reporting of vendor performance.
- Trend analysis identifying performance issues early.
- Governance processes reviewing performance data.
- Clear escalation and CAPA processes for performance failures.
How teams operationalise it
- Define KPIs aligned with vendor responsibilities.
- Track performance metrics regularly.
- Review KPI results through governance meetings.
- Identify and escalate performance issues.
- Implement CAPA where required.
- Ensure ongoing oversight of vendor performance.
From expectation to working control
Find the documentation that supports this work
Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.
Frequently asked questions
How do you monitor pharmacovigilance vendor performance?
Vendor performance is monitored using defined KPIs, regular reporting, governance reviews, audits, and issue tracking processes.
What KPIs are used for PV vendor monitoring?
Common KPIs include ICSR reporting timeliness, case quality, follow-up completion rates, and compliance with regulatory timelines.
How do you measure pharmacovigilance vendor performance?
Vendor performance is measured using defined KPIs such as ICSR reporting timeliness, case quality, follow-up completion, compliance with service levels, and audit outcomes, supported by regular review and trend analysis.
Do inspectors review vendor performance monitoring?
Yes. Inspectors review KPI reports, audit outputs, and governance records to confirm that vendor performance is actively monitored.
What happens if vendor performance drops?
Performance issues should be escalated, investigated, and addressed through corrective and preventive actions.
How often should vendor performance be reviewed?
Vendor performance is typically reviewed monthly or quarterly depending on risk and service criticality.
What evidence is required for vendor performance monitoring?
Evidence includes KPI reports, meeting minutes, audit reports, issue logs, and CAPA documentation.
Source boundary
Regulatory sources
These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.
European Medicines Agency (EMA)
Guideline on good pharmacovigilance practices (GVP) - Module I
View sourceGuideline on good pharmacovigilance practices (GVP) - Module VI
View source
FDA
Postmarketing Safety Reporting
View source
ICH
Post-Approval Safety Data Management (E2D)
View source
MHRA
Good Pharmacovigilance Practice (GPvP)
View source